Annual report pursuant to Section 13 and 15(d)

Fair Value Measurement

v2.4.1.9
Fair Value Measurement
12 Months Ended
Dec. 31, 2014
Fair Value Disclosures [Abstract]  
Fair Value Measurement

ASC 820 defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

 

Level 1 — quoted prices in active markets for identical assets or liabilities.

Level 2 — other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

Level 3 — significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

 

The Company categorized its cash equivalents as Level 1 fair value measurements. As further discussed in Note 5 above, certain of the Company’s marketable securities were subject to restrictions on sale as of December 31, 2014 because they are held in escrow pending resolution of the lease dispute discussion in Note 5. They are considered to be a Level 2 fair value measurement.  The valuation for the 260,000 marketable securities categorized as Level 2 was based on applying a discount for lack of marketability to the quoted market price of the issuer’s unrestricted securities.  The Company categorized its warrants potentially settleable in cash and its options issued to Teva Pharmaceuticals, Inc. as Level 3 fair value measurements. The warrants potentially settleable in cash are measured at fair value on a recurring basis and are being marked to fair value at each reporting date until they are completely settled or meet the requirements to be accounted for as component of stockholders’ equity. The warrants are valued using the Black-Scholes option-pricing model as discussed in Note 10 above.

 

The following table presents a summary of fair values of assets and liabilities that are remeasured at fair value at each balance sheet date as of December 31, 2014 and 2013, and their placement within the fair value hierarchy as discussed above (in thousands):

 

          Quoted Prices in Active Markets   Significant Other Observable Inputs   Unobservable Inputs  
Description   December 31, 2014     (Level 1)     (Level 2)     (Level 3)  
Assets:                        
Cash and cash equivalents   $ 3,970     $ 3,970     $ -     $ -  
Marketable securities     1,975       -       1,975       -  
Total assets   $ 5,945     $ 3,970     $ 1,975     $ -  
                                 
Liabilities:                                
Warrants potentially settleable in cash   $ 8,464     $ -     $ -     $ 8,464  
Total liabilities   $ 8,464     $ -     $ -     $ 8,464  
                                 
            Quoted Prices in Active Markets   Significant Other Observable Inputs   Unobservable Inputs  
Description   December 31, 2013     (Level 1)     (Level 2)     (Level 3)  
Assets:                                
Cash and cash equivalents   $ 1,034     $ 1,034     $ -     $ -  
Total assets   $ 1,034     $ 1,034     $ -     $ -  
                                 
Liabilities:                                
Derivative liability   $ 23     $ -     $ -     $ 23  
Total liabilities   $ 23     $ -     $ -     $ 23  

 

The Company has not transferred any financial instruments into or out of Level 3 classification during the year ended December 31, 2014. A reconciliation of the beginning and ending Level 3 liabilities for the years ended December 31, 2014 and 2013, is as follows (in thousands):

    Fair Value Measurements Using Significant Unobservable Inputs (Level 3)  
    2014     2013  
Balance , January 1,   $ 23     $ 215  
Change in fair value of Teva option     (23 )     (192 )
Estimated fair value of warrants assumed in merger on January 2, 2014     10,475       -  
Estimated fair value of warrants issued in January common stock sale     3,696       -  
Change in fair value of warrants for the year ended December 31, 2014     (5,707 )     -  
Balance at December 31,   $ 8,464     $ 23